ANNX Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Annexon, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.19 |
| 52 Week High | US$8.40 |
| 52 Week Low | US$3.86 |
| Beta | 1.1 |
| 1 Month Change | -2.81% |
| 3 Month Change | -15.47% |
| 1 Year Change | 14.32% |
| 3 Year Change | -54.83% |
| 5 Year Change | n/a |
| Change since IPO | -70.78% |
Recent News & Updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16Shareholder Returns
| ANNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | 0.7% | 0.6% |
| 1Y | 14.3% | -3.4% | 23.8% |
Return vs Industry: ANNX exceeded the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: ANNX underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| ANNX volatility | |
|---|---|
| ANNX Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANNX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 84 | Doug Love | www.annexonbio.com |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
Annexon, Inc. Fundamentals Summary
| ANNX fundamental statistics | |
|---|---|
| Market cap | US$560.68m |
| Earnings (TTM) | -US$117.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs ANNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANNX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$117.50m |
| Earnings | -US$117.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 09:29 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Annexon, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |